Getty ImagesRegeneron is acquiring Checkmate Pharmaceuticals and entered a clinical trial collaboration with SpringWorks Therapeutics to evaluate REGN5458 in multiple myeloma in combination with nirogacestat.
Nektar Therapeutics said on April 14 the company had stopped all clinical trials involving the drug developer’s key cancer drug bempegaldesleukin following its failure in multiple studies, dragging Nektar shares down 23% in after-market trading.
Magenta Therapeutics is reducing the company’s workforce by 14 percent in a revised operating plan to prioritize research and development.
GlaxoSmithKline is acquiring California biopharmaceutical firm Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
The Precision Cancer Consortium (PCC) announced its formation as a new collaboration of pharmaceutical companies with a shared vision of enabling access to comprehensive testing for all cancer patients globally.
Apotex Corp. announced April 12 the company’s release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.
The U.S. Food and Drug Administration placed a partial clinical hold on the TakeAim lymphoma study while the biotech company Curis provides further data to better understand safety and efficacy questions.
Gilead Sciences Inc. said on April 11 the U.S. Food and Drug Administration had lifted the partial clinical hold placed on the company’s trials testing a blood cancer drug combination.
At the Clinical Trials Plenary Session at the 2022 AACR Annual Meeting, Dr. John Haanen, M.D., Ph.D., of the Netherlands Cancer Institute presented data from BioNTech’s ongoing first-in-human Phase I/II trial of the company’s CAR-T cell therapy BNT211 in patients with advanced solid tumors.
